Breaking Finance News

A statement released earlier today by Jefferies International about AstraZeneca PLC (LON:AZN) maintains the target price at 5,800.00GBX

Jefferies International held the target price of AstraZeneca PLC (LON:AZN) at 5,800GBX, stating a possible upside of 0.21%.

On Monday September 12 2016, Jefferies International released a statement for AstraZeneca PLC(LON:AZN) raised the target price from 5,400.00GBX to 5,800.00GBX that indicated a possible upside of 0.19%.

Having a price of 4,813.00GBX, AstraZeneca PLC (LON:AZN) traded 2.02% higher on the day. The last stock price is up 17.65% relative to the 200-day moving average, compared with the S&P 500 Index which has decreased -0.01% over the same time. AstraZeneca PLC has recorded a 50-day moving average of 5,017.86GBX and 200-day average of 4,330.50GBX. Volume of trade was was up over the average, with 4,505,466 shares of AZN changing hands over the typical 2,849,440 shares.

Performance Chart:

AstraZeneca PLC (LON:AZN)

With a market capitalization of 0.0 GBX, AstraZeneca PLC has a one-year low of 3,680.00GBX and a one-year high of 5,505.00GBX with a P/E ratio of 29.

A total of 29 firms have released a report on AstraZeneca PLC. Four analysts rate the stock a strong buy, 14 analysts rate the stock a buy, 13 firms rate the stock a hold, two brokerages rate the stock to underperform, and lastly one brokeragerate the stock as sell with a one year target stock price of 61.96GBX

Brief Synopsis On AstraZeneca PLC (LON:AZN)

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company’s pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, and among others.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.